Corticosteroid-induced myopathy in spinal cord injury patients: a role for anticatabolic agents?
Dickerman
R D
RD
Joseph
A M
AM
Bennett
M T
MT
D045930:Anabolic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors; D004347:Drug Interactions / Q000502:physiology; D006801:Humans; D008775:Methylprednisolone / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D009135:Muscular Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D010074:Oxandrolone / Q000627:therapeutic use*; D011374:Progesterone / Q000494:pharmacology / Q000627:therapeutic use; D013119:Spinal Cord Injuries / Q000188:drug therapy*
D045930:Anabolic Agents; D000893:Anti-Inflammatory Agents; D018696:Neuroprotective Agents; D011374:Progesterone; D010074:Oxandrolone; D008775:Methylprednisolone